Imaging of Endocytic Trafficking and Extracellular Vesicles Released Under Neratinib Treatment in ERBB2
HER2
adjuvant therapy
breast cancer
disease-free survival
electron microscopy
endocytosis
extracellular vesicles
multivesicular bodies
neratinib
tyrosine kinase inhibitors
Journal
The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society
ISSN: 1551-5044
Titre abrégé: J Histochem Cytochem
Pays: United States
ID NLM: 9815334
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
pubmed:
16
6
2021
medline:
7
10
2021
entrez:
15
6
2021
Statut:
ppublish
Résumé
Breast cancers (BCa) with ERBB2 amplification show rapid tumor growth, increased disease progression, and lower survival rate. Deregulated intracellular trafficking and extracellular vesicle (EVs) release are mechanisms that support cancer progression and resistance to treatments. Neratinib (NE) is a Food and Drug Administration-approved pan-ERBB inhibitor employed for the treatment of ERBB2
Identifiants
pubmed: 34126793
doi: 10.1369/00221554211026297
pmc: PMC8246527
doi:
Substances chimiques
Quinolines
0
ERBB2 protein, human
EC 2.7.10.1
Receptor, ErbB-2
EC 2.7.10.1
neratinib
JJH94R3PWB
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
461-473Références
ACS Nano. 2010 Apr 27;4(4):1921-6
pubmed: 20218655
Lancet Oncol. 2016 Mar;17(3):367-377
pubmed: 26874901
Membranes (Basel). 2021 Mar 12;11(3):
pubmed: 33809102
Expert Rev Anticancer Ther. 2017 Aug;17(8):669-679
pubmed: 28649882
Biomed Res Int. 2015;2015:634865
pubmed: 26601108
Cancer Biol Ther. 2018 Jun 3;19(6):525-533
pubmed: 29405820
Cell Death Discov. 2019 Dec 5;5:149
pubmed: 31815004
Cancer Lett. 2016 Nov 28;382(2):176-185
pubmed: 27597738
Analyst. 2015 Oct 7;140(19):6631-42
pubmed: 26332016
Clin Breast Cancer. 2021 Feb;21(1):80-91.e7
pubmed: 33183970
Oncotarget. 2016 Dec 20;7(51):85411-85429
pubmed: 27863425
Oncogene. 2013 Jul 18;32(29):3443-51
pubmed: 22869152
Curr Opin Cell Biol. 2009 Apr;21(2):177-84
pubmed: 19208461
Traffic. 2020 Jan;21(1):76-93
pubmed: 31854087
Clin Cancer Res. 2009 Apr 1;15(7):2552-8
pubmed: 19318484
Nat Rev Cancer. 2005 May;5(5):341-54
pubmed: 15864276
Expert Opin Ther Targets. 2019 Nov;23(11):893-901
pubmed: 31709855
Oncotarget. 2013 Oct;4(10):1592-605
pubmed: 24009064
Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37
pubmed: 11252954
Oncoimmunology. 2017 Aug 11;6(12):e1362530
pubmed: 29209569
J Extracell Vesicles. 2017 Jun 20;6(1):1329476
pubmed: 28717422
J Histochem Cytochem. 2005 Jan;53(1):87-91
pubmed: 15637341
Biochim Biophys Acta Rev Cancer. 2018 Dec;1870(2):123-136
pubmed: 30003999
J Histochem Cytochem. 2012 Aug;60(8):567-75
pubmed: 22562558
J Cell Biol. 2010 Aug 23;190(4):675-91
pubmed: 20713605
Cancers (Basel). 2019 May 28;11(6):
pubmed: 31141894
Br J Cancer. 2021 Jan;124(1):66-75
pubmed: 33262521
Cancer Biol Ther. 2018 Feb 1;19(2):132-137
pubmed: 29219657
Lancet Oncol. 2017 Dec;18(12):1688-1700
pubmed: 29146401
Nat Rev Mol Cell Biol. 2018 Apr;19(4):213-228
pubmed: 29339798
Oncogene. 2019 Jul;38(30):5890-5904
pubmed: 31253872
Nat Biotechnol. 2011 Oct 30;29(11):1046-51
pubmed: 22037378
Mol Biol Cell. 2013 Jan;24(2):129-44
pubmed: 23154999
Cancer Res. 2004 Jun 1;64(11):3958-65
pubmed: 15173008
Cell Signal. 2020 Apr;68:109525
pubmed: 31911180
N Engl J Med. 2007 Jul 5;357(1):39-51
pubmed: 17611206
N Engl J Med. 2012 Nov 8;367(19):1783-91
pubmed: 23020162
Mol Cancer. 2019 Mar 30;18(1):55
pubmed: 30925923
Mol Biol Cell. 2004 Dec;15(12):5268-82
pubmed: 15385631